|
Diabetes, Vol 46, Issue 12 1950-1957, Copyright © 1997 by American Diabetes Association
Effect of captopril, losartan, and bradykinin on early steps of insulin action
CR Carvalho, AC Thirone, JA Gontijo, LA Velloso and MJ Saad
Departamento de Clinica Medica, FCM-UNICAMP, Campinas, Brasil.
Insulin initiates its metabolic and growth-promoting effects by binding to
the alpha subunit of its receptor, thereby activating the kinase in the
beta subunit. This event leads to tyrosyl phosphorylation of its cytosolic
substrate, insulin receptor substrate 1 (IRS-1), which in turn associates
with and activates phosphatidylinositol (PI) 3-kinase. The clinical use of
ACE inhibitors has been associated with increased insulin sensitivity.
However, the exact molecular mechanism is unknown. In the present study, we
examined the phosphorylation status of the insulin receptor and IRS-1, as
well as the association between IRS-1 and PI 3-kinase in the liver and
muscle of 20-month-old rats treated acutely with captopril, using
immunoprecipitation with antipeptide antibodies to the insulin receptor and
IRS-1, and immunoblotting with antiphosphotyrosine and anti-PI 3-kinase
antibodies. Insulin stimulation increased receptor autophosphorylation to
462 +/- 253% (P < 0.05) in the liver and 697 +/- 78% (P < 0.001) in
the muscle of ACE inhibitor-treated rats. There were also increases to 250
+/- 17% (P < 0.001) and 280 +/- 50% (P < 0.05) in the
insulin-stimulated IRS-1 phosphorylation levels in the liver and muscle,
respectively, of animals treated with captopril. The insulin-stimulated
IRS-1 association with PI 3-kinase rose to 305 +/- 20% (P < 0.001) in
liver and 267 +/- 48% (P < 0.05) in muscle. Losartan, an ANG receptor
blocker, had no significant effect on insulin-stimulated IRS-1
phosphorylation in both tissues. The acute administration of bradykinin
increased insulin-stimulated tyrosine phosphorylation of the insulin
receptor and IRS-1 in the liver and muscle. These data demonstrate that ACE
inhibitors modulate the early steps of insulin signaling, and that this
effect may be simulated by the administration of bradykinin.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. J. Henriksen
Improvement of insulin sensitivity by antagonism of the renin-angiotensin system
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 2007;
293(3):
R974 - R980.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Giani, M. M. Gironacci, M. C. Munoz, C. Pena, D. Turyn, and F. P. Dominici
Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors
Am J Physiol Heart Circ Physiol,
August 1, 2007;
293(2):
H1154 - H1163.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Beard, H. Lu, K. Ho, and I. G. Fantus
Bradykinin Augments Insulin-Stimulated Glucose Transport in Rat Adipocytes via Endothelial Nitric Oxide Synthase-Mediated Inhibition of Jun NH2-Terminal Kinase.
Diabetes,
October 1, 2006;
55(10):
2678 - 2687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Wong, L. Szeto, K. Uffelman, I G. Fantus, and G. F Lewis
Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway.
J. Endocrinol.,
August 1, 2006;
190(2):
441 - 450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Lupi, S. D. Guerra, M. Bugliani, U. Boggi, F. Mosca, S. Torri, S. D. Prato, and P. Marchetti
The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets
Eur. J. Endocrinol.,
February 1, 2006;
154(2):
355 - 361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor
Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance
J. Gerontol. A Biol. Sci. Med. Sci.,
November 1, 2005;
60(11):
1437 - 1446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. C. Calegari, M. Alves, P. K. Picardi, R. Y. Inoue, K. G. Franchini, M. J. A. Saad, and L. A. Velloso
Suppressor of Cytokine Signaling-3 Provides a Novel Interface in the Cross-Talk between Angiotensin II and Insulin Signaling Systems
Endocrinology,
February 1, 2005;
146(2):
579 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Carter, M. Cesari, W. T. Ambrosius, N. Hu, D. Diz, S. Oden, W. E. Sonntag, and M. Pahor
Angiotensin-Converting Enzyme Inhibition, Body Composition, and Physical Performance in Aged Rats
J. Gerontol. A Biol. Sci. Med. Sci.,
May 1, 2004;
59(5):
B416 - B423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Okamoto, D. H. Sumida, C. R. O. Carvalho, A. M. Vargas, J. C. Heimann, B. D'A. Schaan, and U. F. Machado
Changes in dietary sodium consumption modulate GLUT4 gene expression and early steps of insulin signaling
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2004;
286(4):
R779 - R785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Wang, N. Leung, N. Lapointe, L. Szeto, K. D. Uffelman, A. Giacca, J. L. Rouleau, and G. F. Lewis
Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats: Studies Comparing a Vasopeptidase Inhibitor, Angiotensin-Converting Enzyme Inhibitor, and Angiotensin II Type I Receptor Blocker
Circulation,
April 15, 2003;
107(14):
1923 - 1929.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Brown, S. Kumar, C. A. Painter, and D. E. Vaughan
ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time
Hypertension,
December 1, 2002;
40(6):
859 - 865.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shiuchi, T.-X. Cui, L. Wu, H. Nakagami, Y. Takeda-Matsubara, M. Iwai, and M. Horiuchi
ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse Via Bradykinin and NO
Hypertension,
September 1, 2002;
40(3):
329 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Duka, S. Shenouda, C. Johns, E. Kintsurashvili, I. Gavras, and H. Gavras
Role of the B2 Receptor of Bradykinin in Insulin Sensitivity
Hypertension,
December 1, 2001;
38(6):
1355 - 1360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Foianini, M. S. Steen, T. R. Kinnick, M. B. Schmit, E. B. Youngblood, and E. J. Henriksen
Effects of exercise training and ACE inhibition on insulin action in rat skeletal muscle
J Appl Physiol,
August 1, 2000;
89(2):
687 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. B. Reis, F. G. R. Reyes, M. J. A. Saad, and L. A. Velloso
Magnesium Deficiency Modulates the Insulin Signaling Pathway in Liver but Not Muscle of Rats
J. Nutr.,
January 1, 2000;
130(2):
133 - 138.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. d. O. Prada, M. M. Okamoto, L. N. S. Furukawa, U. F. Machado, J. C. Heimann, and M. S. Dolnikoff
High- or Low-Salt Diet From Weaning to Adulthood : Effect on Insulin Sensitivity in Wistar Rats
Hypertension,
January 1, 2000;
35(1):
424 - 429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Brown, M. Agirbasli, and D. E. Vaughan
Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans
Hypertension,
August 1, 1999;
34(2):
285 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Henriksen, S. Jacob, T. R. Kinnick, E. B. Youngblood, M. B. Schmit, and G. J. Dietze
ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide
Am J Physiol Regulatory Integrative Comp Physiol,
July 1, 1999;
277(1):
R332 - R336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Steen, K. R. Foianini, E. B. Youngblood, T. R. Kinnick, S. Jacob, and E. J. Henriksen
Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats
J Appl Physiol,
June 1, 1999;
86(6):
2044 - 2051.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bonora, G. Targher, M. Alberiche, R. C. Bonadonna, F. Saggiani, M. B. Zenere, S. Uleri, and M. Muggeo
Effect of Chronic Treatment with Lacidipine or Lisinopril on Intracellular Partitioning of Glucose Metabolism in Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab.,
May 1, 1999;
84(5):
1544 - 1550.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. J. Henriksen, S. Jacob, D. L. Fogt, and G. J. Dietze
Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance
Am J Physiol Regulatory Integrative Comp Physiol,
July 1, 1998;
275(1):
R40 - R45.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Diabetes Association.
|
|
| |
|